Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as ...

Sutro Biopharma (STRO) announced the completion of a strategic portfolio review resulting in the prioritization of its three wholly-owned ...

Sutro Biopharma reported $62 million in 2024 revenue, down from $153.7 million in 2023, and announced a pipeline restructuring.

Sutro Biopharma (STRO) stock falls as the company announces portfolio review, CEO appointment and headcount reduction. Read ...

EPIC-B: Phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma. Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease ...

New research reveals that visceral adipose tissue helps maintain brain-derived neurotrophic factor (BDNF) levels, but this ...